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Abstract
Background—Melanoma is the most common malignancy encountered during pregnancy. 
Conflicting data have led to ongoing confusion regarding pregnancy associated melanoma (PAM) 
in the media and among the public. The objective of this study was to better characterize both the 
clinical presentation of PAM and its prognostic implications.
Study Design—Female patients of reproductive age with stage 0-IV cutaneous melanoma were 
identified from our prospectively maintained database. Clinical and histopathologic factors were 
analyzed with appropriate statistical methods. Univariable and then multivariable analysis were 
utilized on matched data to compare disease free survival (DFS), overall survival (OS) and 
melanoma specific survival (MSS) for stage 0-III PAMs vs non-PAMs. Kaplan-Meier survival 
curves were then plotted for OS and MSS and compared using the log-rank test.
Results—Clinical presentation of melanoma was similar for PAM and non-PAM patients. There 
was no significant difference in recurrence between the two groups; for PAMs, 38.5% of patients 
recurred as compared to 36.6% of non-PAMs (p=0.641). For PAMs, median follow up was 14.6 
years (range 0–42.6 years) and 11.1 years (0 – 48.5 years) for the non-PAMs. No significant 
differences in DFS, MSS, or OS were identified on univariable or multivariable analysis for PAM 
vs non-PAMs in stage 0/I/II and stage III cutaneous melanoma respectively (p=0.880 DFS, 
p=0.219 OS and p=0.670 MSS).
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Conclusions—We observed no difference in DFS, OS or MSS between the two groups. 
Pregnant patients should be screened for melanoma in a similar manner to non-pregnant patients 
and should be counseled that their survival is not adversely affected by their pregnancy.
Keywords
Melanoma; Pregnancy; overall survival; melanoma specific survival; disease free survival
Introduction
Melanoma is the most common malignancy encountered during pregnancy, accounting for 
31% of all malignancies in the intrapartum period. (1, 2) For many years, pregnancy has 
been thought to have an adverse effect on the course of melanoma. Reports beginning in the 
1950s suggested pregnancy increased the risk of melanoma development, metastasis and 
recurrence. (3–6) Many hypotheses since then have been formulated, linking worsened 
outcomes to hyperpigmentation, relative immunosuppression, and hormone binding of 
melanocytes. (7–10) Given the overall increase in melanoma incidence in women of 
childbearing age in the US, this topic has become even more pertinent. (11, 12) Editorials, 
systemic reviews, and media coverage of PAM persist but fail to draw definitive conclusions 
despite many years of attention and underpowered studies. (13–21) Many of the adequately 
powered studies that do exist come from large, non-US based registries, with a resultant lack 
of granular detail and reliability. (22–25) The primary objective of this study was to query 
our large, single institution melanoma database to better characterize PAM with particular 
attention to overall survival (OS) and melanoma specific survival (MSS). Secondarily, we 
examined other clinical factors with regard to melanoma mortality and such as parity and 
gravidity, in addition to known prognostic factors such as age, stage, histologic type, 
Breslow thickness, and ulceration.
Methods
Female patients of reproductive age (18–50) with American Joint Committee on Cancer 
(AJCC) stage 0-IV cutaneous melanoma were identified from the prospectively maintained 
John Wayne Cancer Institute melanoma database between January 1971 and May 2016. All 
patient data were de-identified, and this study was independently confirmed to be exempt 
from Institutional Review Board review. Melanomas were staged by seventh edition AJCC 
criteria. (26–28) In order to ensure adequate staging, patients without lymph node staging 
for melanomas with Breslow thickness ≥0.75 mm were excluded from analysis (n=540 non-
PAM, n=43 PAM). Pregnancy associated melanoma is a field derived either from patient 
questionnaire responses (self reported) or direct physician queries (physician reported). The 
JWCI melanoma database defines PAMs by an affirmative response to “did melanoma 
develop during pregnancy.” This includes cases that developed de novo during pregnancy or 
melanomas that arose from pre-existing lesions that changed during pregnancy. We cannot 
exclude the possibility that some of these lesions were identified incidentally during prenatal 
visits. Laboratory pregnancy confirmation is incomplete in this data set as patients receiving 
office based excisions would not have routinely received urine or serum pregnancy 
evaluations. For this reason, we are not able to comment on the women who were deemed 
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pregnant based on preoperative bHCG alone. Clinical and histopathologic factors were 
examined between PAM and non-PAM groups. T-test was used to analyze age at diagnosis, 
parity, gravidity, and Breslow thickness. Chi-square test was used for Clark level, anatomic 
site, ulceration, sentinel lymph node examination status, recurrence status, type of first 
recurrence, stage at diagnosis, and stage first seen at JWCI. A 1:1 matched pair sample was 
then created using pairs of PAM and non-PAM patients who were matched for Breslow 
thickness, age, stage and ulceration status. With respect to age, we matched utilizing the 
following categories: <25, 25 – =35, ≥3. With respect to Breslow thickness, we matched for 
categories: ≤ 0.75, 0.75 – <2.00, 2.00 – ≤4.00, > 4.00 and unknown. For stage at diagnosis, 
we matched using categories: 0, I/II, and III. Finally, for ulceration, we matched using 
categories: yes, no and unknown. These details have been incorporated in to the manuscript 
on page 4. Univariable and then multivariable analyses were conducted with the matched 
data to analyze DFS, OS and MSS for patients with stage 0/I/II and stage III cutaneous 
melanoma at diagnosis. Due to the paucity of PAM patients with Stage IV disease at 
diagnosis (n=1), those patients were excluded from this analysis. Kaplan-Meier survival 
curves were then plotted for OS and MSS and compared using the log-rank test. SAS 
software, version 9.3 (SAS Institute) was used for all analyses. A two-sided p-value of 0.05 
or lower was considered to indicate statistical significance.
Results
Of the entire patient cohort (n=2025), 156 women (7.7%) with PAM were identified after 
selection criteria applied. No cases of transplacental transfer of melanoma were identified. 
Clinical presentation of melanoma was similar for PAM and non-PAM patients with no 
significant differences in Breslow thickness (1.30 mm vs. 1.34 mm, p=0.737), histologic 
type, or primary tumor site (see Table 1). Age was greater in the non-PAM patients (36.8 vs 
31.7 years, p<0.001). There was also no significant difference in stage at diagnosis. (Table 1) 
Parity was significantly increased in the PAM group, p=0.010, as was gravidity, p<0.001 At 
10-years; disease-free survival was 65.7% and 62.3% for the non-PAM and PAM groups, 
respectively (p=0.8934). Mean disease-free survival was also similar at 24.48 years in the 
non-PAM group and 20.65 years in the PAM group.
Matched Pair Sample
In an attempt to decrease potential biases associated with delay in diagnosis of PAMs, we 
created a matched pair sample. Each PAM patient was matched with a non-PAM patient by 
Breslow thickness, age, stage and ulceration status. In this group of 310 patients (155 
matched pairs), PAMs had a median follow-up of 14.6 years (range 0–42.6 years), and non-
PAMs had a median follow-up of 11.1 years (0 – 48.5 years). When comparing the PAM and 
non-PAM matched pairs, clinical features were similar (see Table 2) except for histologic 
type (p=0.046), primary site (p=0.040), gravidity and parity (p<0.001, p<0.001). There were 
also no differences in recurrence between the PAM and non-PAM group (Table 2).
Univariable Survival Analysis by Stage
For matched patients with stage 0/I/II melanoma at diagnosis, there were no differences 
identified in DFS (p=0.880, HR 0.97, 95% CI 0.62–1.5), OS (p=0.219, HR 0.73, 95% CI 
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0.44–1.21) or MSS (p=0.670, HR 0.89, 95% CI 0.51–1.53) for PAMs. For those patients 
with stage III melanoma at diagnosis, there were no differences in DFS (p=0.858, HR 0.94, 
95% CI 0.46–1.93) OS (p=0.365, HR 0.64 95% CI 0.24–1.69) or MSS (p=0.595, HR 0.75, 
95% CI 0.26–2.17) for PAMs. Concordant results were obtained when Kaplan-Meier curves 
were plotted and compared using log-rank test for OS and MSS for both stage 0/I/II at 
diagnosis (Figure 1) and stage III at diagnosis (data not shown).
Expected differences in DFS, OS and MSS with regard to increasing Breslow thickness, 
stage first seen, ulceration, Clark level, histologic type and recurrence data (Tables 3–5) 
were identified for patients with stage 0/I/II melanoma at diagnosis. For patients with stage 
III melanoma at diagnosis, none of the clinicopathologic factors assessed were significantly 
associated with significant DFS, OS or MSS differences except for ulceration.
Univariable Reproductive History and Survival Differences
Interestingly, increasing gravidity was associated with worse DFS (p=0.026, HR 1.18, 95% 
CI 1.02–1.36), OS (p=0.042 HR 1.19 95% CI 1.01–1.40) and MSS (p=0.034, HR 1.21 95% 
CI 1.02–1.44) for stage 0/I/II melanomas, but these differences were not seen for stage III 
patients. Conversely, when parity was examined, there were no significant differences in 
DFS (p=0.330, HR 1.07, 95% CI 0.93–1.24), OS (p=0.562, HR 1.05 95% CI 0.88–1.26) or 
MSS (p=0.556 HR 1.06 95% CI 0.88–1.28) for stage 0/I/II melanomas. There were also no 
significant differences in OS or MSS for stage III patients with respect to parity as an 
independent prognostic factor.
Multivariable Survival Analysis by Stage
For patients with stage 0/I/II or stage III melanoma at diagnosis, there were no significant 
differences identified in DFS, OS or MSS for PAMs in the model (Tables 3–5, not shown). 
The only factors associated with significant differences in OS were ulceration (yes or 
unknown) and increasing Breslow thickness for stage 0/I/II melanoma. (Table 3) For MSS, 
factors associated with significant differences in OS were trunk as primary site (p=0.016, 
HR 2.22, 95% CI 1.16–4.23), Breslow thickness 2-≤4 and >4 (p<0.001 HR 5.62, 2.05–
15.35, and p<0.001, HR141.76, 95% CI 21.47–936.05), ulceration (yes: p<0.001, HR 6.83 
95% CI 2.38–9.96; unknown: p<0.01, HR 4.87, 95% CI 1.27–5.15) and increasing gravidity 
(p=0.027, HR 1.24, 95% CI 1.03–1.51). For DFS, the only factors associated with 
significant differences on multivariable analysis were also expected: increasing Breslow 
thickness, trunk as the primary site (p=0.007, HR 1.91, 95% CI 1.19–3.06) and histologic 
type (SSM, In situ, and other) for stage 0/I/II melanoma. (See Table 5) There were no factors 
associated with significant differences in Stage III patients with respect to DFS, OS and 
MSS on multivariable analysis.
Discussion
Despite previous study, controversy remains for women of childbearing age at risk for or 
diagnosed with cutaneous melanoma. In our institutional analysis, the incidence of PAM was 
7.7%, congruent with previous work from this institution identifying a 8.7 percent incidence 
of PAM. (29) In early 2016, Tellez and colleagues reported that women with melanoma 
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arising during or within one year of childbirth had a significantly worse prognosis when 
compared to their non-pregnant counterparts. (30) This study was limited by its small, 
retrospective nature; additionally, only 19 of 41 patients in the study had melanoma 
diagnosed during pregnancy. Based on multivariable analysis of this limited sample, the 
authors reported a 9-fold increase in recurrence (odds ratio (OR) 9.30, p=0.01), a 7-fold 
increase in metastasis (OR 6.70, p=0.01) and a 5-fold increase in mortality (OR 5.10, 
p=0.03). (30)
Larger studies have been published, however, that refute this notion of diminished survival 
for PAMs. In 2004, O’Meara et al. evaluated 412 women with PAM from California 
maternal and neonatal discharge records linked to California Cancer Registry data. After 
controlling for age, race, stage, and tumor thickness, pregnancy had no impact on survival in 
women with melanoma. This held true for those during pregnancy (p=0.570) or in the 
postpartum period (p=0.162). (23) Johansson and colleagues used Swedish Cancer and 
Multi-Generation Registers to conduct a population-based cohort study examining 1019 
PAMs. However, the definition of PAM in this study was broad, including patients with 
melanoma arising during pregnancy or up to two years following delivery. (24) This group 
showed no significant difference in survival (p=0.47) for PAMs vs non-PAMs in this study 
of women aged 15–44. (24) Similarly, in 2004, Lens et al. examined 185 PAMs using data 
from the Swedish National and Regional Registries. This group also found no significant 
difference in overall survival between PAMs and non-PAMs (p=0.84, log rank test). At 
multivariable cox regression, pregnancy at the time of melanoma diagnosis was not related 
to increased risk of death (p=0.804, HR 1.08, 95% CI 0.60–1.93). Prognostic factors for 
these women were Breslow thickness (p<0.001, HR 2.16 95% CI 1.80–2.58) and axial vs 
limb site of the primary melanoma (p<0.001, HR 2.51 95% CI 1.78–3.56). (22)
In this study, as expected, Breslow thickness was associated with worsened OS and MSS in 
Stage 0/I/II patients. (Tables 3 and 4) A criticism of previous studies linking melanoma with 
abject survival outcomes was the preponderance of thicker tumors in PAM patients, possibly 
due to delay in diagnosis. Travers et al., in 1995, queried patient records from the 
Massachusetts General Hospital and identified 45 women with PAM. This group reported 
significantly greater mean tumor thickness in PAMs than non-PAMs (2.28 vs 1.22 mm, 
p<0.007). (31) While the authors stated that “the mechanisms by which pregnancy may lead 
to increased thickness of melanoma remain unclear…” they do acknowledge that a delay in 
diagnosis may have led to the thicker lesions identified in PAM cases. (31) When examining 
incidence and outcomes of 577 PAMs from registry data in New South Wales, Bannister-
Tyrrell and colleagues showed that melanomas diagnosed in pregnancy were thicker (median 
= 0.75 mm) than melanomas diagnosed postpartum (median = 0.60 mm, p = 0.002). (25) 
When we controlled for this potential confounder by matching for Breslow thickness, no 
difference in survival outcomes were identified for PAMs as compared to non-PAMs. 
Additionally, by excluding patients without lymph node staging for lesions ≥ 0.75 mm in 
Breslow thickness, our group limited the proportion of patients receiving non-standard care. 
Mackie et al. reported similar findings with regard to Breslow thickness in a study of 388 
women of childbearing age with melanoma (92 treated during pregnancy) from the World 
Health Organization melanoma programme. These authors concluded that Breslow thickness 
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was greater in women who were diagnosed while pregnant (p=0.002), however once 
Breslow thickness was controlled for, survival rates did not differ (p=0.1). (32)
To our knowledge, this is the first study associating increased gravidity to worsened survival 
outcomes in women of childbearing age with stage 0/I/II melanoma. Mechanisms 
underlying this finding could be associated with hormonal differences or other un-
characterized risk factors associated with gravidity. Future study will be needed to fully 
examine this association in a prospective manner. Also of note, while we do not have 
consistent or reliably documented follow up for babies born to these mothers with PAM, no 
cases of transplacental melanoma have been identified in the JWCI melanoma database 
comprising approximately 15,600 patients to date. Compared to larger registry-based 
studies, our data comes from a well-maintained and reliable single institution database with 
extensive follow up. Additionally, we excluded patients with melanomas ≥ 0.75 mm thick 
who did not receive nodal staging, thereby limiting non-standard care and inaccurately 
staged lesions. In contrast to previous studies that were not matched for pertinent factors 
such as Breslow thickness, age, and stage; our study was not clouded by these known 
prognostic factors.
Limitations of this study include its retrospective nature and treatment-related biases 
inherent to our referral center. Additionally, the majority of patients evaluated exhibited 
favorable prognostic factors and few PAMs had stage III disease or thick primary tumors 
(n=17 and n=5 respectively). Finally, due to the time period over which this data was 
collected, some subjects did not have complete data with regard to histology, ulceration and 
lymph node staging exam, which introduces some amount of uncertainty with regards to 
their initial prognosis. Despite these limitations, we believe this work accurately reflects 
PAM incidence and outcomes.
Conclusions
This, the largest, single-institution study examining the characteristics and outcomes 
associated with melanoma arising during pregnancy demonstrates no significant difference 
in DFS, OS or MSS. Pregnant patients should be screened for melanoma in a similar manner 
to non-pregnant patients and should be counseled that their prognosis is not adversely 
affected by pregnancy.
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Figure 1. 
Kaplan-Meier survival curves from stage 0, I, and II matched date, for (A) overall survival 
and (B) melanoma specific survival. p Values calculated by log rank test. PAM, pregnancy-
associated melanoma.
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Table 1
Whole Group Frequency
Non-PAM PAM p Value
n 2,025 156
Age at diagnosis, y, mean ± SD 36.76 ± 8.43 31.69 ± 8.69 <0.001
Age, n (%) <0.001
 <25 y 215 (10.62) 20 (12.82)
 25 – ≤35 y 611 (30.17) 101 (64.74)
 ≥35 y 1199 (59.21) 35 (22.44)
Stage at diagnosis, n (%) 0.186
 0 138 (6.81) 5 (3.21)
 I/II 1647 (81.33) 134 (85.90)
 III 240 (11.85) 17 (10.90)
Primary site, n (%) 0.100
 Head/neck 193 (9.53) 8 (5.13)
 Trunk 733 (36.20) 66 (42.31)
 Extremity 1099 (54.27) 82 (52.56)
Breslow thickness, mm, n (%) 0.311
 ≤ 0.75 711 (35.11) 55 (35.26)
 0.75 – <2.00 518 (25.58) 43 (27.56)
 2.00 – ≤4.00 177 (8.74) 20 (12.82)
 > 4.00 75 (3.70) 5 (3.21)
 Unknown 544 (26.86) 33 (21.15)
Breslow thickness (mm), continuous, mean ± SD 1.34 ± 1.58 1.30 ± 1.21 0.737
Para, mean ± SD 1.36 ± 1.46 1.68 ± 1.44 <0.001
Gravida, mean ± SD 1.78 ± 1.71 2.29 ± 1.51 <0.001
Ulceration, n (%) 0.849
 Yes 173 (8.54) 12 (7.69)
 No 1381 (68.20) 105 (67.31)
 Unknown 471 (23.26) 39 (25.00)
Clark level, n (%) 0.025
 I 183 (9.04) 9 (5.77)
 II 546 (26.96) 43 (27.56)
 III 493 (24.35) 37 (23.72)
 IV 495 (24.44) 54 (34.62)
 V 51 (2.52) 1 (0.64)
 Unknown 257 (12.69) 12 (7.69)
Histologic type, n (%) 0.228
 ALM/LMM 38 (1.88) 1 (0.64)
 In situ 138 (6.81) 5 (3.21)
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Non-PAM PAM p Value
 NM 241 (11.90) 21 (13.46)
 SSM 972 (48.00) 84 (53.85)
 Others 78 (3.85) 3 (1.92)
 Unknown 558 (27.56) 42 (26.92)
Lymph nodes examined, n (%) 0.540
 Positive 248 (12.25) 18 (11.54)
 Negative 830 (40.99) 71 (45.51)
 Not done 947 (46.77) 67 (42.95)
Type of first recurrence, n (%) 0.656
 None 1284 (63.47) 96 (61.54)
 Nodal 412 (20.37) 38 (24.36)
 Local/in-transit 125 (6.18) 8 (5.13)
 Distant 202 (9.99) 14 (8.97)
PAM, pregnancy associated melanoma; ALM, acral lentiginous melanoma; LMM, lentigo maligna melanoma; NM, nodular melanoma; SSM, 
superficial spreading melanoma
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Table 2
Matched Sample Frequency
Non-PAM PAM p Value
n 155 155
Age,y, n (%)
 <25 20 (12.90) 20 (12.90)
 25 – ≤35 100 (64.52) 100 (64.52)
 ≥35 35 (22.58) 35 (22.58)
Stage at diagnosis, n (%)
 0/I/II 139 (89.68) 139 (89.68)
 III 16 (10.32) 16 (10.32)
Breslow thickness, mm, n (%)
 ≤ 0.75 55 (35.48) 55 (35.48)
 0.75 – <2.00 43 (27.74) 43 (27.74)
 2.00 – ≤4.00 20 (12.90) 20 (12.90)
 > 4.00 5 (3.23) 5 (3.23)
Ulceration, n (%)
 Yes 12 (7.74) 12 (7.74)
 No 104 (67.10) 104 (67.10)
 Unknown 39 (25.16) 39 (25.16)
Age at diagnosis , y, mean ± SD 32.17 ± 6.79 31.72 ±8.71 0.616
Stage first seen, n (%) 0.137
 0 14 (9.09) 5 (3.25)
 I/II 94 (61.04) 108 (70.13)
 III 31 (20.13) 28 (18.18)
 IV 15 (9.74) 13 (8.44)
 Unknown 1 (0.01) 1 (0.01)
Primary site, n (%) 0.040
 Head/neck 21 (13.55) 8 (5.16)
 Trunk 61 (39.35) 66 (42.58)
 Extremity 73 (47.10) 81 (52.26)
Breslow thickness, mm, continuous, mean ± SD 1.48 ± 1.94 1.30 ± 1.21 0.389
Para, mean ± SD 0.89 ± 1.22 1.68 ± 1.45 <0.001
Gravida, mean ± SD 1.24 ± 1.45 2.30 ± 1.52 <0.001
Clark level, n (%) 0.258
 I 11 (7.10) 9 (5.81)
 II 43 (27.74) 43 (27.74)
 III 39 (25.16) 37 (23.87)
 IV 38 (24.52) 53 (34.19)
 V 4 (2.58) 1 (0.65)
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Non-PAM PAM p Value
 Unknown 20 (12.90) 12 (7.74)
Histologic type, n (%) 0.046
 ALM/LMM 2 (1.29) 1 (0.65)
 In situ 14 (9.03) 5 (3.32)
 NM 23 (14.84) 21 (13.55)
 SSM 59 (38.06) 84 (54.19)
 Others 2 (1.29) 3 (1.94)
 Unknown 55 (35.48) 41 (26.45)
Lymph nodes examined, n (%) 0.627
 Positive 17 (10.97) 17 (10.97)
 Negative 79 (50.97) 71 (45.81)
 Not done 59 (38.06) 67 (43.23)
PAM, pregnancy associated melanoma; ALM, acral lentiginous melanoma; LMM, lentigo maligna melanoma; NM, nodular melanoma; SSM, 
superficial spreading melanoma
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Table 3
Overall Survival Stage 0/I/II at diagnosis: Matched Data
Univariable Multivariable
p Value Hazard ratio (95% CI) p Value Hazard ratio (95% CI)
Age in years (increasing) 0.103 1.03 (0.99, 1.06)
Location
Extremity (Reference)
Head/Neck 0.440 1.52 (0.53, 4.37)
Trunk 0.215 1.43 (0.81, 2.50)
Breslow thickness (mm) ≤ 0.75 (Reference)
 0.75 – <2.00 0.020 2.68 (1.17, 6.14) 0.067 2.05 (0.95, 4.39)
 2.00 – ≤4.00 <0.001 7.59 (3.23, 17.83) <0.001 4.73 (2.10, 10.66)
 >4.00 <0.001 40.03 (8.2,4 194.46) <0.001 49.20 (10.24, 236.39)
 Unknown 0.018 2.75 (1.19, 6.36) 0.067 1.98 (0.95, 4.12)
Breslow thickness (mm), continuous <0.001 1.74 (1.40, 2.18)
Para 0.562 1.05 (0.88, 1.26)
Gravida 0.042 1.19 (1.01, 1.40)
PAM 0.219 0.73 (0.44, 1.21)
Stage first seen
 0 NA* NA*
 I/II (Reference)
 III <0.001 4.91 (2.53, 9.56)
 IV <0.001 17.45 (9.05, 33.62)
Ulceration
 Yes <0.001 8.49 (3.79, 19.02) <0.001 5.19 (2.18, 12.34)
 No (Reference)
 Unknown 0.009 2.20 (1.22, 3.97) <0.001 3.18 (1.82, 5.55)
Clark Level
 I (Reference)
 II 0.113 5.23 (0.68, 40.50)
 III 0.018 11.26 (1.50, 84.28)
 IV 0.007 16.50 (2.17, 125.44)
 V NA*
 Unknown <0.001 45.88 (5.74, 366.92)
Histologic type
 ALM/LMM 0.86 0.83 (0.11, 6.54)
 In Situ NA*
 NM (Reference)
 SSM 0.003 0.32 (0.15, 0.67)
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Univariable Multivariable
p Value Hazard ratio (95% CI) p Value Hazard ratio (95% CI)
 Others 0.448 0.45 (0.06, 3.53)
 Unknown 0.413 0.73 (0.34, 1.56)
*NA, Not applicable: analysis not available due to small sample size.
PAM, pregnancy associated melanoma; ALM, acral lentiginous melanoma; LMM, lentigo maligna melanoma; NM, nodular melanoma; SSM, 
superficial spreading melanoma
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Table 4
Melanoma-Specific Survival Stage 0/I/II at Diagnosis: Matched Data
Univariable Multivariable
p Value Hazard ratio (95% CI) p Value Hazard ratio (95% CI)
Age in years (increasing) 0.189 1.03 (0.99, 1.06)
Location
 Extremity (Reference)
 Head/neck 0.261 1.85 (0.63, 5.42)
 Trunk 0.157 1.54 (0.85, 2.81) 0.016 2.22 (1.16, 4.23)
Breslow thickness (mm), continuous <0.001 1.77 (1.39, 2.24)
Breslow category (mm)
  ≤ 0.75 (Reference)
 0.75 – <2.00 0.015 3.07 (1.24, 7.62)
 2.00 – ≤4.00 <0.001 8.45 (3.32, 21.49) <0.001 5.62 (2.05, 15.38)
 > 4.00 <0.001 44.69 (8.89, 224.68) <0.001 141.76 (21.47, 936.05)
 Unknown 0.015 3.20 (1.26, 8.13)
Para 0.556 1.06 (0.88, 1.28)
Gravida 0.034 1.21 (1.02, 1.44) 0.027 1.24 (1.03, 1.51)
PAM 0.670 0.89 (0.51, 1.53)
Stage first seen
 0 NA*
 I/II (Reference)
 III <0.001 6.63 (3.27, 13.48)
 IV <0.001 21.18 (10.59, 42.36)
Ulceration
 Yes <0.001 10.12 (4.42, 23.17) <0.001 6.83 (2.38 9.96)
 No (Reference)
 Unknown 0.007 2.38 (1.26, 4.47) <0.001 4.87 (1.27, 5.15)
Clark Level
 I NA*
 II (Reference)
 III 0.040 2.35 (1.04, 5.32)
 IV 0.003 3.56 (1.52, 8.34)
 V NA*
 Unknown <0.001 11.30 (4.35, 29.34)
Histologic type
 NM (Reference)
 SSM 0.004 0.31 (0.14, 0.68)
 Others 0.534 0.52 (0.07, 4.10)
 Unknown 0.487 0.76 (0.34, 1.68)
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PAM, pregnancy associated melanoma; ALM, acral lentiginous melanoma; LMM, lentigo maligna melanoma; NM, nodular melanoma; SSM,
superficial spreading melanoma
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Table 5
Disease-Free Survival Stage 0/II/II at Diagnosis: Matched Data
Univariable Multivariable
p Value Hazard ratio (95% CI) p Value Hazard ratio (95% CI)
Age in years (increasing) 0.739 1.01 (0.97 – 1.04)
Location
 Extremity (Reference)
 Head/neck 0.007 2.57 (1.30–5.09)
 Trunk 0.027 1.69 (1.06–2.70) 0.007 1.91 (1.19–3.06)
Breslow thickness (mm) (continuous) <0.001 1.74 (1.43–2.13)
Breslow category (mm)
 ≤ 0.75 (Reference)
 0.75 – <2.00 0.021 2.18 (1.12–4.23) 0.009 2.47 (1.25–4.89)
 2.00 – ≤4.00 <0.001 5.51 (2.72–11.15) <0.001 4.28 (1.87–9.85)
 > 4.00 <0.001 18.60 (4.17–82.85) <0.001 22.50 (4.86–104.21)
 Unknown <0.001 4.22 (2.26–7.87) <0.001 3.95 (2.01–7.74)
Para 0.330 1.07 (0.931–1.24)
Gravida 0.026 1.18 (1.02–1.36)
PAM 0.880 0.97 (0.62–1.50)
Stage first seen
 0 0.500 0.50 (0.07–3.71)
 I/II (Reference)
 III <0.001 12.78 (7.5–21.77)
 IV <0.001 12.15 (7.00–21.11)
Ulceration
 Yes <0.001 4.19 (1.86–9.45)
 No (Reference)
 Unknown <0.001 2.92 (1.86–4.60)
Clark Level
 I NA*
 II (Reference)
 III 0.068 2.01 (0.95–4.26)
 IV <0.001 3.90 (1.95–7.82)
 V 0.176 4.12 (0.53–32.08)
 Unknown <0.001 8.88 (4.34–18.15)
Histologic type
 ALM/LMM NA*
 NM (Reference)
 In Situ 0.022 0.09 (0.01–0.71)
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Univariable Multivariable
p Value Hazard ratio (95% CI) p Value Hazard ratio (95% CI)
 SSM <0.001 0.22 (0.12–0.43)
 Others 0.070 3.15 (0.91–10.82)
 Unknown 0.619 0.87 (0.49–1.53)
*NA, sample size too small for comparison.
PAM, pregnancy associated melanoma; ALM, acral lentiginous melanoma; LMM, lentigo maligna melanoma; NM, nodular melanoma; SSM, 
superficial spreading melanoma
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